PDS Biotechnology (PDSB) Gets a Buy Rating from Noble Financial


Noble Financial analyst Ahu Demir reiterated a Buy rating on PDS Biotechnology (PDSB) today and set a price target of $6.60. The company’s shares closed last Thursday at $2.10.

According to TipRanks.com, Demir is a 4-star analyst with an average return of 24.5% and a 39.1% success rate. Demir covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Onconova Therapeutics, and Dyadic International.

PDS Biotechnology has an analyst consensus of Moderate Buy, with a price target consensus of $6.30, representing a 187.7% upside. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $6.00 price target.

See today’s analyst top recommended stocks >>

Based on PDS Biotechnology’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $2.93 million. In comparison, last year the company had a GAAP net loss of $3.89 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded on March 15, 2019 and is headquartered in Berkeley Heights, NJ.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts